These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

579 related articles for article (PubMed ID: 23996108)

  • 1. Ruxolitinib for the treatment of myelofibrosis: a NICE single technology appraisal.
    Wade R; Rose M; Neilson AR; Stirk L; Rodriguez-Lopez R; Bowen D; Craig D; Woolacott N
    Pharmacoeconomics; 2013 Oct; 31(10):841-52. PubMed ID: 23996108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Review of Ruxolitinib for the Treatment of Myelofibrosis: A Critique of the Evidence.
    Wade R; Hodgson R; Biswas M; Harden M; Woolacott N
    Pharmacoeconomics; 2017 Feb; 35(2):203-213. PubMed ID: 27592020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal.
    Yang H; Craig D; Epstein D; Bojke L; Light K; Bruce IN; Sculpher M; Woolacott N
    Pharmacoeconomics; 2012 Apr; 30(4):257-70. PubMed ID: 22283690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence.
    Wade R; Duarte A; Simmonds M; Rodriguez-Lopez R; Duffy S; Woolacott N; Spackman E
    Pharmacoeconomics; 2015 May; 33(5):457-66. PubMed ID: 25616671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Morgan P; Woolacott N; Biswas M; Mebrahtu T; Harden M; Hodgson R
    Pharmacoeconomics; 2017 Sep; 35(9):909-919. PubMed ID: 28342113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Clinical and Cost Effectiveness of Vortioxetine for the Treatment of a Major Depressive Episode in Patients With Failed Prior Antidepressant Therapy: A Critique of the Evidence.
    Lomas J; Llewellyn A; Soares M; Simmonds M; Wright K; Eastwood A; Palmer S
    Pharmacoeconomics; 2016 Sep; 34(9):901-12. PubMed ID: 27289476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal.
    Burch J; Griffin S; McKenna C; Walker S; Paton J; Wright K; Woolacott N
    Pharmacoeconomics; 2012 Nov; 30(11):991-1004. PubMed ID: 22950547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alitretinoin for severe chronic hand eczema: a NICE single technology appraisal.
    Rodgers M; Griffin S; Paulden M; Slack R; Duffy S; Ingram JR; Woolacott N; Sculpher M
    Pharmacoeconomics; 2010; 28(5):351-62. PubMed ID: 20131924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Clinical and Cost Effectiveness of Ustekinumab for the Treatment of Psoriatic Arthritis: A Critique of the Evidence.
    O'Connor J; Rice S; Smith A; Rodgers M; Lopez RR; Craig D; Woolacott N
    Pharmacoeconomics; 2016 Apr; 34(4):337-48. PubMed ID: 26818809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal.
    Boyers D; Jia X; Jenkinson D; Mowatt G
    Pharmacoeconomics; 2012 Jun; 30(6):483-95. PubMed ID: 22480381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trabectedin for the treatment of advanced metastatic soft tissue sarcoma: a NICE single technology appraisal.
    Rafia R; Simpson E; Stevenson M; Papaioannou D
    Pharmacoeconomics; 2013 Jun; 31(6):471-8. PubMed ID: 23568332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal.
    Whyte S; Pandor A; Stevenson M
    Pharmacoeconomics; 2012 Dec; 30(12):1119-32. PubMed ID: 23058097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
    Harrison C; Kiladjian JJ; Al-Ali HK; Gisslinger H; Waltzman R; Stalbovskaya V; McQuitty M; Hunter DS; Levy R; Knoops L; Cervantes F; Vannucchi AM; Barbui T; Barosi G
    N Engl J Med; 2012 Mar; 366(9):787-98. PubMed ID: 22375970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ipilimumab for Previously Untreated Unresectable Malignant Melanoma: A Critique of the Evidence.
    Giannopoulou C; Sideris E; Wade R; Moe-Byrne T; Eastwood A; McKenna C
    Pharmacoeconomics; 2015 Dec; 33(12):1269-79. PubMed ID: 26043718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.
    Mesa RA; Gotlib J; Gupta V; Catalano JV; Deininger MW; Shields AL; Miller CB; Silver RT; Talpaz M; Winton EF; Harvey JH; Hare T; Erickson-Viitanen S; Sun W; Sandor V; Levy RS; Kantarjian HM; Verstovsek S
    J Clin Oncol; 2013 Apr; 31(10):1285-92. PubMed ID: 23423753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dronedarone for the treatment of atrial fibrillation: a NICE single technology appraisal.
    McKenna C; Maund E; Sarowar M; Fox D; Stevenson M; Pepper C; Woolacott N; Palmer S
    Pharmacoeconomics; 2012 Jan; 30(1):35-46. PubMed ID: 22136303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
    Verstovsek S; Mesa RA; Gotlib J; Levy RS; Gupta V; DiPersio JF; Catalano JV; Deininger M; Miller C; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner E; Lyons RM; Paquette R; Raza A; Vaddi K; Erickson-Viitanen S; Koumenis IL; Sun W; Sandor V; Kantarjian HM
    N Engl J Med; 2012 Mar; 366(9):799-807. PubMed ID: 22375971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene.
    Blommestein HM; Armstrong N; Ryder S; Deshpande S; Worthy G; Noake C; Riemsma R; Kleijnen J; Severens JL; Al MJ
    Pharmacoeconomics; 2016 Jan; 34(1):23-31. PubMed ID: 26314282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.
    Verstovsek S; Mesa RA; Gotlib J; Gupta V; DiPersio JF; Catalano JV; Deininger MW; Miller CB; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner EO; Lyons RM; Paquette R; Raza A; Jones M; Kornacki D; Sun K; Kantarjian H;
    J Hematol Oncol; 2017 Feb; 10(1):55. PubMed ID: 28228106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daclatasvir for the Treatment of Chronic Hepatitis C: A Critique of the Clinical and Economic Evidence.
    Llewellyn A; Faria R; Woods B; Simmonds M; Lomas J; Woolacott N; Griffin S
    Pharmacoeconomics; 2016 Oct; 34(10):981-92. PubMed ID: 27278217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.